SectorBiological Technology
Established Date--
Listing Date20/09/2017
ExchangeNASDAQ Stock Exchange
Full-time Employees87
Fiscal Year Ends31/12
Security TypeCommon stock
Office address16305 36th , Avenue North, Suite 100, Minneapolis, MN 55446
Business
IntroductionCelcuity Inc., is incorporated in Delaware. The company is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of a variety of solid tumor indications. The Company's primary therapeutic candidate is gedatolisib, a potent, well-tolerated small molecule reversible inhibitor that, when administered intravenously, selectively targets all class I isomers of phosphatidyl inositol 3-kinase (PI3K) and mTORC1 and mTORC2, two mechanistic targets of rapamycin (mTOR). The mechanism of action and pharmacokinetic properties of Gedatolisib are very different from currently approved and under development therapies that target PI3K or mTOR alone or together.
